Schering Corporation

Baxter International Inc.

American Home Products Corporation

Baxter Healthcare Sa

Pui-Ho C Yuen

Charles G Eckhart

Nancy Levine

Teresa Etlinger

Douglas F Kline

Joel A Sequeira

Peter M Ihnat

Gary J Vellekamp

Andreas Frei

Michael A Zupon

Jianwei Yu

Varda E Sandweiss

Mary Mathew George

Alan S Kirschner

Henry K H Kwan

Shreeram Agharkar

Kiran Pal Singh

Virginia Paulate

Martin A Joyce

A pharmaceutical formulation suitable for multi-dose administration comprising endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxanide hydrochloride, a preservative selected from the group consisting of alkyl paraben and phenol, and a buffer selected from the group consisting of acetate and phosphate buffers is disclosed.

Pharmaceutical formulations of endo-N-(9-methyl-9-azabicyclo[3,3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride

Compositions and methods are provided for reducing adverse reactions as a result of parenteral administration of certain phenothiazine derivatives such as promethazine, including promethazine hydrochloride. The active compound may be admixed with an effective amount of one or more non-ionic surfactants and at least one amino acid and/or one polyol prior to administration to an animal such as a mammal.

Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma using surfactants and amino acids

A composition is disclosed comprising virus in a formulation comprising a polyhydroxy hydrocarbon buffered to maintain a pH in a range from about 7 to about 8.5 at a temperature in the range from about 2&deg; C. to 27&deg; C. Methods for concentrating and purifying virus preparations are also disclosed.

Compostions comprising viruses and methods for concentrating virus preparations

The invention relates to the novel compound mometasone furoate monohydrate, process for its preparation and pharmaceutical compositions containing said compound.

Process for making mometasone furoate monohydrate

Sterile pharmaceutical compositions parenteral administration containing propofol in an oil-in-water emulsion additionally containing an amount of the preservative tromethamine sufficient to prevent signficant growth of microorganisms for at least 24 hours after extrinsic contamination.

Propofol formulation containing TRIS

Mometasone furoate monohydrate, process for making same and

Stable aqueous solution formulations containing alfa-interferon type interferon, e.g., interferon alfa-2a and interferon alfa-2b, a buffer to maintain the pH in the range of 4.5-7.1, polysorbate 80 as a stabilizer, edetate disodium as a chelating agent, sodium chloride as a tonicity agent, and m-cresol as an antimicrobial preservative and which maintain high chemical, physical and biological stability of the alfa-type interferon for an extended storage period of at least 24 months are disclosed.

Stable aqueous alfa interferon solution formulations

Process for making stable aqueous solution formulations containing alfa-type interferon, e.g., interferon alfa-2a and interferon alfa-2b, a buffer to maintain the pH in the range of 4.5-7.1, polysorbate 80 as a stabilizer, edetate disodium as a chelating agent, sodium chloride as a tonicity agent, and m-cresol as an antimicrobial preservative and which maintain high chemical, physical and biological stability of the alfa interferon for an extended storage period of at least 24 months are disclosed.

Stable, aqueous alfa interferon solution formulations

A process for preparing aqueous parenteral compositions of drugs which are weak bases and are only slightly soluble in water is disclosed. Aqueous parenteral compositions of the antifungal agent (.+-.) (2R*, 3R*)-2-(2,4-difluorophenyl)-3-methylsulfonyl-1-(1,2,4-triazol-1-yl)butan-2 -ol are also disclosed.

Parenteral compositions

Buffered aqueous solution of thimerosal wherein the buffer is citric acid and sodium citrate having a pH between 3.5 and 7.

Stable solutions containing thimerosal

Disclosed is a kit for preparing a lyophilized alpha interferon gel formulation suitable for topical administration.

Growing community of inventors

Princeton Junction, NJ, United States of America

Pui-Ho C Yuen